# reload+after+2024-01-23 15:43:27.263605
address1§177 East Colorado Boulevard
address2§Suite 700
city§Pasadena
state§CA
zip§91105
country§United States
phone§626 304 3400
fax§626 304 3401
website§https://arrowheadpharma.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.
fullTimeEmployees§525
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Christopher R. Anzalone Ph.D.', 'age': 54, 'title': 'CEO, President & Director', 'yearBorn': 1969, 'fiscalYear': 2022, 'totalPay': 1649420, 'exercisedValue': 996462, 'unexercisedValue': 14937168}, {'maxAge': 1, 'name': 'Mr. Kenneth A. Myszkowski', 'age': 57, 'title': 'Chief Financial Officer', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 761552, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': "Mr. Patrick  O'Brien J.D., PharmD", 'age': 59, 'title': 'COO, General Counsel & Secretary', 'yearBorn': 1964, 'fiscalYear': 2022, 'totalPay': 749863, 'exercisedValue': 172200, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. James C. Hamilton M.D., MBA', 'age': 45, 'title': 'Chief of Discovery & Translational Medicine', 'yearBorn': 1978, 'fiscalYear': 2022, 'totalPay': 676814, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Tracie  Oliver', 'title': 'Chief Commercial Officer', 'fiscalYear': 2022, 'totalPay': 449579, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Mark M. Davis Ph.D.', 'title': 'Founder and Founder & Director of Insert Therapeutics Inc & Calando', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Vincent  Anzalone CFA', 'title': 'Head of Investor Relations & VP', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Howard  Lovy', 'title': 'Director of Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Mark  Seefeld', 'age': 69, 'title': 'Head of Toxicology & VP', 'yearBorn': 1954, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Javier  San Martin M.D.', 'age': 58, 'title': 'Chief Medical Officer', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 658480, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§9
boardRisk§8
compensationRisk§3
shareHolderRightsRisk§1
overallRisk§4
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.793
priceToSalesTrailing12Months§15.887092
currency§USD
dateShortInterest§1702598400
forwardEps§-3.15
pegRatio§-1.45
exchange§NMS
quoteType§EQUITY
shortName§Arrowhead Pharmaceuticals, Inc.
longName§Arrowhead Pharmaceuticals, Inc.
firstTradeDateEpochUtc§756052200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§c1090240-5c7b-33ae-b362-c474642e552e
gmtOffSetMilliseconds§-18000000
targetHighPrice§90.0
targetLowPrice§24.0
targetMeanPrice§54.21
targetMedianPrice§54.0
recommendationMean§2.1
recommendationKey§buy
numberOfAnalystOpinions§14
quickRatio§3.753
grossMargins§1.0
ebitdaMargins§-0.79967004
trailingPegRatio§None
